Abstract. The histone deacetylase inhibitor trichostatin A (TSA) has been demonstrated to alleviate certain symptoms associated with osteoarthritis (OA). However, the exact mechanisms underlying this protective effect remain to be elucidated. The present study therefore examined the effects of TSA on the expression levels of interleukin-1β (IL-1β)-induced matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in vitro and in vivo. In vitro, reverse transcription-quantitative polymerase chain reaction was performed to investigate alterations in mRNA expression levels in TSA-treated chondrocytes in the presence or absence of IL-1β; in addition, protein expression and acetylation levels were assessed by western blotting. In vivo, TSA was administered to rats by intra-articular injection, following which the mRNA and protein expression levels were analyzed. In addition, macroscopic and histological observations were conducted. Chondrocytes treated with IL-1β demonstrated increased mRNA and protein expression levels of MMP-1, MMP-3 and MMP-13, and decreased expression levels of TIMP-1 mRNA and protein; these alterations were significantly attenuated by TSA treatment. In addition, increased MMPs and decreased TIMP-1 expression levels were observed in vivo in the OA rat model. TSA treatment demonstrated in vivo efficacy through the attenuation of various OA-associated molecular and physiological changes. Taken together, the results of the present study suggest that TSA has potential therapeutic value for the treatment of OA.
Introduction
Osteoarthritis (OA), the predominant form of arthritis (1) , is characterized by slow, progressive joint degeneration. It is a primary cause of continuous pain and chronic disability that restricts the normal daily lives of many elderly individuals (2) (3) (4) . Although there are numerous risk factors for OA, including obesity, aging and trauma, the mechanisms underlying these associations remain to be elucidated (5) (6) (7) . Previous studies have demonstrated that synthesis and catabolism disorders in chondrocytes are involved in the onset of OA (8, 9) . It is generally accepted that the loss of articular cartilage matrix components, including collagen type II and aggrecan, resulting from the activation of proteolytic enzymes, such as matrix metalloproteinases (MMPs), is a frequent characteristic of OA (10) (11) (12) (13) (14) . MMPs are a family of endopeptidases that contribute to numerous physiological processes via the degradation of extracellular matrix components. MMP-1 and MMP-13, also referred to as collagenases, degrade all types of collagen, particularly those that supply mechanical strength to tissues, such as collagen type II in articular cartilage (14, 15) . MMP-3, also referred to as pro-MMP, is a type of stromelysin that activates other MMPs, including MMP-1 and MMP-13 (16) . The biological activities of MMPs are antagonized by tissue inhibitors of metalloproteinases (TIMPs), such as TIMP-1 (17, 18) . Thus, an imbalance in the activities of MMPs and TIMPs is considered to be critical in OA progression (19, 20) .
Inflammatory cytokines, including interleukin (IL)-1β, tumor necrosis factor-α and IL-6, are crucial for chondrocyte apoptosis and degradation of the extracellular matrix (21, 22) , and are thus involved in the pathogenesis and development of OA. A previous study has confirmed that IL-1β induces upregulation of MMPs and downregulation of TIMPs, resulting in degradation of proteoglycans and collagen (21) .
Trichostatin A (TSA), originally developed as an antifungal agent (23) , is a non-selective histone deacetylase inhibitor (HDACi) (24, 25) . The acetylation of lysine residues on histones H3 and H4 opens the chromatin structure to promote active gene transcription (26) (27) (28) (29) . The regulation of inflammatory genes by TSA has attracted considerable attention. Previous studies have demonstrated that TSA exerts anti-OA and anti-rheumatoid arthritis effects via suppression of the expression of MMPs, cyclooxygenase-2, inducible nitric Trichostatin A increases the TIMP-1/MMP ratio to protect against osteoarthritis in an animal model of the disease oxide synthase and a disintegrin and MMP with thrombospondin motifs (4, 30) . Furthermore, it has been revealed that the underlying anti-inflammatory mechanism may involve inhibition of the mitogen-activated protein kinase and nuclear factor-κB (NF-κB) signaling pathways, and subsequent upregulation of sirtuin 1 expression (31). However, the underlying mechanism by which TSA ameliorates the OA inflammatory response remains to be fully elucidated, and there is currently not enough evidence to determine whether the anti-OA effect of TSA involves altering the level of acetylation in chondrocytes. Therefore, the present study investigated the association between the anti-OA effects of TSA and the levels of acetylation in chondrocytes.
Materials and methods
R e a g e n t s . T SA a n d I L -1β w e r e p u r c h Isolation and culture of rat chondrocytes. Rat cartilage was collected from the knee and hip joints of six 2-week-old female Sprague Dawley rats (weight, 35-45 g) from the Zhejiang Academy of Medical Sciences (Hangzhou, China). Rats were housed under pathogen-free conditions at room temperature (22-25˚C) and 50% humidity, and has a 12-h light/dark cycle. Food and water were offered ad libitum. To isolate chondrocytes, rat cartilage was digested with 0.2% collagenase II (Sigma-Aldrich) in DMEM for 4 h at 37˚C. Rat cartilage was subsequently filtered through a 150 µm mesh filter and centrifuged at 300 x g for 5 min at 4˚C, and chondrocytes were then collected and cultured in DMEM with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin in a 5% CO 2 atmosphere at 37˚C. Chondrocytes at passage 3 were used for all analyses, according to a previous study (32) .
Determination of TSA concentration. To select the optimal TSA concentration for the in vitro and in vivo experiments, cell viability in the presence of TSA was evaluated using the Cell Counting kit-8 (CCK-8; Dojindo Molecular Technologies, Inc., Kumamoto, Japan) assay. Cells were seeded in 96-well plates at 6x10 3 cells/well and allowed to adhere overnight. Cells were then cultured in various concentrations of TSA in diluted in serum-free DMEM for 24 h. The medium was then removed, and 10 µl CCK-8 solution in 90 µl fresh medium was added to each well. Following incubation for 3 h at 37˚C the absorbance was measured at 450 nm using a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Treatment of rat chondrocytes. Chondrocytes were seeded in 6-well plates at 2x10 5 cells/well. At 80% confluency, they were serum-starved for 12 h. Cells were then pre-treated with various concentrations of TSA for 2 h, and stimulated with IL-1β (5 ng/ml) for 12 h or left unstimulated. Cells were harvested for mRNA expression analysis of MMPs and TIMP-1. For determination of total protein and acetylation levels of MMPs and TIMP-1, IL-1β stimulation was maintained for 24 h.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. Briefly, total RNA was extracted from cell and cartilage samples with TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). RNA (0.5 µg) was reversed-transcribed to cDNA using the PrimeScript-RT reagent kit (Takara Bio, Inc., Otsu, Japan). cDNA samples were amplified and quantified by qPCR (ABI Prism 7500; Applied Biosystems; Thermo Fisher Scientific, Inc.) using the SYBR Premix Ex Taq (Takara Bio, Inc.). qPCR protocol cycling conditions were as follows: Holding stage, 95˚C for 30 sec; cycling stage, 95˚C for 5 sec, then 60˚C for 30 sec, for a total of 40 cycles. Stage Primers for MMP-1, MMP-3, MMP-13, TIMP-1, and 18S ribosomal RNA (18S rRNA) genes were obtained from Sangon Biotech Co., Ltd. (Shanghai, China); the sequences are listed in Table I . 18S rRNA served as an internal control. Relative expression was calculated using the 2 -ΔΔCq method (33) .
Western blot analysis. Cell and cartilage samples were washed twice with ice-cold phosphate-buffered saline (PBS). Proteins were then extracted using radioimmunoprecipitation assay lysis buffer (Wuhan Boster Biological Technology, Ltd., Wuhan, China) for 30 min. Protein levels were quantified with the Pierce Bicinchoninic Acid Protein assay (Thermo Fisher Scientific, Inc.). Proteins (5 µg) were resolved by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) at 110 V for 90 min, and transferred to polyvinylidene difluoride membranes. Following incubation in blocking buffer (5% non-fat milk) for 1 h at room temperature, the membranes were sectioned based on molecular weights, and probed with the following primary antibodies: Rabbit-anti β-actin (catalog no., DW130656; Hang Zhou Dawen Biotec Co., Ltd., Hangzhou, China), rabbit-anti MMP-1 (catalog no., BS1229; Bioworld Technology, Inc., Louis Park, MN, USA), rabbit-anti MMP-3 (catalog no., 17,873-1-AP; ProteinTech Group, Inc., Chicago, IL, USA), rabbit-anti MMP-13 (catalog no., BS6668; Bioworld Technology, Inc.), rabbit-anti TIMP-1 (catalog no., sc-5538; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), and mouse anti-H3 (96C10, catalog no., #3638), mouse anti-H4 (L64C1, catalog no., #2935), rabbit anti-acetyl-H3 (Lys27, catalog no., #8173), and rabbit anti-acetyl-H4 Animal study. A total of 30 4-week-old male Sprague Dawley rats (weight, 120-140 g), from the Animal Center at Zhejiang University (Hangzhou, China), were used in the present study. Experiments were conducted with the approval of the Zhejiang University Animal Care and Use Committee (Hangzhou, China). Rats were housed under pathogen-free conditions at room temperature (22-25˚C) and 50% humidity, and had a 12-h light/dark cycle. Food and water were offered ad libitum. Rats were randomly divided into three groups: i) Control, ii) OA and iii) TSA-treated. Following anesthesia with 2% pentobarbital sodium (0.1 ml/100 g; Sigma-Aldrich) (34) , rats in the OA and TSA-treated groups received an intra-articular injection of mono-iodoacetate (MIA; 1 mg in 50 µl PBS; Sigma-Aldrich) into the knee joint (35) . Rats in the control group were injected with 50 µl PBS. Three days later, rats in the TSA-treated group were bilaterally intra-articularly injected into the knees with 50 µl TSA (0.2 µM), while the other groups received 50 µl PBS injected intra-articularly. These injections were repeated once a week for four weeks. All of the rats were sacrificed seven days following the final injection. Mice were anaesthetized with 2% pentobarbital sodium (0.1 ml/100 g; Sigma-Aldrich) and cervical vertebrae were dislocated. Then femoral condyles were collected for gene and protein expression analysis and histological assessment.
Histological analysis. Specimens were fixed in 4% paraformaldehyde in 0.1 M PBS for 72 h (31) and decalcified with 10% buffered formic acid at room temperature for two months. Specimens were embedded in paraffin wax and cut into 5 mm sections. The sections were stained with Safranin-O and fast green (36) . The Mankin scoring system was used for blinded histological assessment (36) .
Statistical analysis. Data are expressed as the mean ± standard deviation. Comparisons were made using an unpaired Student's t-test and one-way analysis of variance, followed by Dunnett's analysis. P<0.05 was considered to indicate a statistically significant difference.
Results
Assessment of TSA concentrations. To select the optimal concentrations of TSA for in vitro and in vivo experiments, a CCK-8 assay was performed to evaluate various TSA concentrations. As presented in Fig. 1 , TSA concentrations <0.4 µM exerted no significant effect on chondrocyte viability at 24 h (0.8 vs. 0 µM TSA; P= 0.03), and therefore were selected for use in subsequent experiments. 
TSA decreases MMP and increases

TSA treatment delays knee joint degeneration in the rat OA model and is accompanied by decreased MMP and increased TIMP-1 mRNA and protein expression levels in cartilage.
The gross appearance of femoral condyles collected from the various treatment groups were examined (Fig. 3A) . The condyle surface in the control group was intact and glossy. By contrast, the condyle surface of rats in the OA group revealed gross morphological alterations, including defects, osteophytes and tissue adhesions. Notably, a marked reversion to normal morphology was observed in the TSA-treated group. Morphological analysis was accompanied by Safranin-O/fast green staining of cartilage (Fig. 3B) . Compared with the control group, Safranin-O staining was largely absent in the OA group (demonstrated by the absence of red staining in the OA group image). TSA administration markedly restored Safranin-O staining, indicative of cartilage retention, although not to the level of the control group. TSA treatment markedly attenuates numerous changes associated with OA progression, as measured by the Figure 3 . Effect of TSA on the rat OA model and on MMP-1, MMP-3, MMP-13 and TIMP-1 mRNA and protein expression levels in cartilage. An in vivo study was performed using Sprague Dawley rats, which were randomly divided into three groups (n=10/group): Control, OA and OA with TSA treatment.
(A) Representative images of macroscopic observations. (B) Safranin-O/fast green staining (magnification, x100). (C) Total RNA was isolated from cartilage, and reverse transcription-quantitative polymerase chain reaction was performed to determine relative mRNA expression levels. Levels were calculated using the 2 -ΔΔCq method and expressed as the mean ± SD. * P<0.05 vs. OA. (D) Proteins were extracted from cartilage for western blot analysis, and bands were quantified using densitometry and quantity one software. Data are expressed as the mean ± SD. TSA, trichostatin A; OA, osteoarthritis; MMP, matrix metalloproteinase; TIMP-1, tissue inhibitor of metalloproteinases-1; SD, standard deviation.
Mankin scoring system for histological analyses (Table II) . Structural and cellular changes were analyzed and assigned histological scores. The sum of the scores was significantly increased in the OA group (7.47±1.07) compared with the control (1.02±0.18; P= 0.005). Notably, and consistent with our earlier findings (4, 30) , TSA treatment promoted reversion back to normal, with a sum of 3.01±0.41 (P= 0.003 vs. OA group). Molecular analyses of in vivo samples were performed. Results from RT-qPCR revealed that mRNA expression levels of MMP-1, MMP-3 and MMP-13 were significantly upregulated, and TIMP-1 was downregulated, in cartilage from OA rats compared with control rats (Fig. 3C) . Consistent with the in vitro observations, TSA treatment significantly attenuated the OA-associated alterations in expression levels of each of these genes (P<0.05). Alterations in protein expression levels of MMPs and TIMP-1 were consistent with the RT-qPCR data (P<0.05; Fig. 3D ).
TSA increases acetylation levels in chondrocytes and cartilage. Data from the in vitro and in vivo experiments indicate that TSA may be beneficial in the treatment of OA. As TSA is an HDACi, alterations in levels of acetylation in cells (Fig. 4A and B) and in the OA animal model (Fig. 4C) were examined. Levels of acetylation at H3K27 and H4K8 were not significantly altered in cells treated with IL-1β or in cartilage from the OA group, indicating that acetylation at these specific residues is not involved in OA progression. Notably, TSA administration significantly increased acetylation at these residues, providing evidence of functional TSA treatment (P<0.05).
Discussion
The results of the present study revealed that TSA significantly attenuated the IL-1β-induced upregulation of MMP-1, MMP-3 and MMP-13, and the downregulation of TIMP-1. In addition, the level of acetylation increased in a TSA dose-dependent manner, independent of IL-1β treatment. Consistent with these observations in vitro, increased expression levels of MMP-1, MMP-3 and MMP-13, and decreased TIMP-1 expression levels, were detected in the OA rat model compared with control rats. These findings suggest that the altered MMP/TIMP-1 ratio is an important contributing factor in OA progression. In addition, TSA treatment demonstrated a beneficial effect in vivo, possibly via an increase in TIMP-1 expression levels. Furthermore, levels of acetylated histones, H3 and H4 were increased in the TSA-treated group compared with the OA and control groups. These observations in vitro and in vivo suggest that TSA treatment alters the MMP/TIMP-1 ratio to protect against OA. These conclusions are supported by the function of TIMP-1 as an important inhibitor of MMP activity during the process of cartilage degeneration (37) . MMPs degrade various extracellular matrix components, including collagen type II, which is a key pathological feature of OA (38) .
In the present study, the role of histone acetylation in OA progression and following TSA treatment was examined. Analyses were limited to acetylation of H3K27 and H4K8. Acetylation of these residues was not identified to be significantly altered in vitro by IL-1β treatment or in vivo in the OA rat model. These findings suggest that altered histone acetylation of these specific residues is not involved in OA development and progression. Alternatively, alterations in acetylation of these residues may occur only at key genes involved in OA and, as such, may not be observable at the global level when probed by western blot analysis. However, increased acetylation of the two residues following TSA treatment in vitro and in vivo was observed. In addition, while TSA treatment increased TIMP-1 expression levels, it had no direct effect on expression levels of MMP-1, MMP-3 or MMP-13. This suggests that TSA attenuates the OA-associated increase in MMPs via upregulating TIMP-1, rather than by directly affecting MMP transcription. Previous studies have demonstrated that histone hyperacetylation is associated with anti-inflammatory properties (39) via altered gene expression (40) . A similar mechanism of action may underlie the anti-OA effect of TSA that was observed in in the present study. However, this hypothesis requires additional investigation. In future experiments, analysis of a larger panel of histone acetylation modifications and chromatin immunoprecipitation would be performed to determine which genes are marked by histone modifications. This would facilitate the determination of the precise underlying mechanism of action of TSA in the protection against OA.
The results of the present study revealed that TSA treatment does not significantly alter transcript levels of MMP-1, MMP-3 and MMP-13. These findings suggest that MMP transcription in this setting is not directly linked to histone acetylation. Consistent with this, a previous study demonstrated that the IL-1β-mediated production of MMPs primarily occurs via the NF-κB signaling pathway (41) . However, in our previous study on the effect of TSA on the NF-κB signaling pathway in chondrocytes treated with IL-1β, no significant alterations in NF-κB activity were observed (32) . Additional experiments are therefore required to determine the exact underlying mechanism by which the anti-OA effects of TSA are exerted. In conclusion, the results of the present study demonstrated that TSA protects against OA formation in chondrocytes in vitro and in an in vivo OA rat model. It is proposed that TSA functions via the upregulation of TIMP-1 and subsequent inhibition of MMP activity. The findings of the present study suggest that TSA may be a potential therapy for the treatment of OA, and that histone acetylation may be an important contributing factor in this disease.
